177 related articles for article (PubMed ID: 34376997)
1. Acquired
Yao B; Han X; Pang L; Xu C; Liu S; Cheng X; Chen J
Onco Targets Ther; 2021; 14():4329-4333. PubMed ID: 34376997
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Next-Generation ALK Inhibitors Fuels Plasma
Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT
Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
4. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
5. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report.
De Carlo E; Schiappacassi M; Urbani M; Doliana R; Baldassarre G; Da Ros V; Santarossa S; Chimienti E; Berto E; Fratino L; Bearz A
Onco Targets Ther; 2018; 11():8945-8950. PubMed ID: 30573982
[TBL] [Abstract][Full Text] [Related]
7. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
8. Complex genetic alterations contribute to rapid disease progression in an
Long X; Wu H; Yang C; Li F; Zhang M; Wu X
Transl Cancer Res; 2021 Jun; 10(6):3081-3086. PubMed ID: 35116617
[TBL] [Abstract][Full Text] [Related]
9. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Dagogo-Jack I; Brannon AR; Ferris LA; Campbell CD; Lin JJ; Schultz KR; Ackil J; Stevens S; Dardaei L; Yoda S; Hubbeling H; Digumarthy SR; Riester M; Hata AN; Sequist LV; Lennes IT; Iafrate AJ; Heist RS; Azzoli CG; Farago AF; Engelman JA; Lennerz JK; Benes CH; Leary RJ; Shaw AT; Gainor JF
JCO Precis Oncol; 2018; 2018():. PubMed ID: 29376144
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
11. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Christopoulos P; Dietz S; Angeles AK; Rheinheimer S; Kazdal D; Volckmar AL; Janke F; Endris V; Meister M; Kriegsmann M; Zemojtel T; Reck M; Stenzinger A; Thomas M; Sültmann H
Transl Lung Cancer Res; 2021 May; 10(5):2118-2131. PubMed ID: 34164264
[TBL] [Abstract][Full Text] [Related]
12. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
13. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting
Mezquita L; Swalduz A; Jovelet C; Ortiz-Cuaran S; Howarth K; Planchard D; Avrillon V; Recondo G; Marteau S; Benitez JC; De Kievit F; Plagnol V; Lacroix L; Odier L; Rouleau E; Fournel P; Caramella C; Tissot C; Adam J; Woodhouse S; Nicotra C; Auclin E; Remon J; Morris C; Green E; Massard C; Pérol M; Friboulet L; Besse B; Saintigny P
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923908
[TBL] [Abstract][Full Text] [Related]
15. Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy.
Sasaki T; Yoshida R; Nitanai K; Watanabe T; Tenma T; Kida R; Mori C; Umekage Y; Hirai N; Minami Y; Okumura S
Transl Lung Cancer Res; 2023 Jul; 12(7):1445-1453. PubMed ID: 37577301
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
17. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
Sim J; Kim H; Hyeon J; Choi Y; Han J
J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
[TBL] [Abstract][Full Text] [Related]
20. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
